Brief: Astellas Pharma Inc- Recording Of Extraordinary Losses In Non-Consolidated Financial Results
04/02/2025 23:33
Feb 5 (Reuters) - Astellas Pharma Inc 4503.T :
* ASTELLAS PHARMA INC- RECORDING OF EXTRAORDINARY LOSSES IN
NON-CONSOLIDATED FINANCIAL RESULTS
* ASTELLAS PHARMA INC- RECORDED 60.6 BILLION YEN OF
EXTRAORDINARY
LOSSES IN NON-CONSOLIDATED FINANCIAL RESULTS DUE TO SIGNIFICANT
DECLINE IN VALUE OF SHARES OF SUBSIDIARY GANYMED
PHARMACEUTICALS GMBH
Source text: ID:nTSnd8974f
Further company coverage: 4503.T
(Reporting by Rocky Swift)
((rocky.swift@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn